Actively Recruiting
18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer
Led by M.D. Anderson Cancer Center · Updated on 2026-05-19
60
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating if 18F-FAraG PET scans can detect tumors in people with esophageal cancer and predict how they respond to chemoradiation treatment. This phase 1 study aims to assess the imaging tracer's ability to identify cancer and forecast complete pathologic response, along with correlations with clinical features, tissue and blood biomarkers, and survival outcomes. Participants will receive a 18F-FAraG PET scan before starting their standard treatment. About 20 minutes before the scan, they will drink water to help clear the tracer from their kidneys. The tracer is given by intravenous injection. Standard imaging will also be done before treatment begins to compare with the research scan. During the study, researchers will monitor safety and adverse events for about one year. Participants will undergo the 18F-FAraG PET scan and standard imaging to evaluate tumor detection and treatment response. Blood and tissue samples may be collected to study biomarkers. The study tracks overall and disease-free survival as part of the long-term follow-up.
CONDITIONS
Brief Title
18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must be 18 years of age or older
- Participants with locally advanced esophageal cancer
- Participants with untreated documented carcinoma of the esophagus larger than 2 cm who will receive systemic therapy concurrently with radiation as primary therapy
- Ability to provide written informed consent
- Female participants of childbearing potential must have a negative pregnancy test within 1 week prior to investigational PET/CT scan
- Female participants of childbearing potential must agree to use adequate contraception prior to and during study participation
You will not qualify if you...
- Body weight 400 pounds or more or body habitus or disability preventing imaging protocol
- Pregnant or lactating females
- History of allergic reaction to intravenous contrast
- Estimated glomerular filtration rate (eGFR) less than 40 within 1 month prior to receiving 18F-FAraG PET
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Duration of chemoradiation treatment
Participants receive the 18F-FAraG PET scan and standard-of-care chemoradiation treatment to evaluate tumor response.
1 baseline 18F-FAraG PET scan and standard-of-care imaging before treatment
Duration - Up to 1 year after treatment completion
Participants are monitored for safety, adverse events, and treatment response up to approximately 1 year after treatment completion.
Periodic visits for safety and response assessments
Trial Site Locations
Total: 1 location
1
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
S
Steven Lin, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here